Lisa Dietz

USPTO Granted Patents = 16 (Patent Applications = 22)

EPO Patents = 9 (Patent Applications = 29)

Average Co-Inventor Count = 10.4

ph-index = 3

Forward Citations = 21(Granted Patents)

Company Filing History:

15 out of 378

Bayer Pharma Aktiengesellschaft

patents

7 out of 12,157

Bayer Aktiengesellschaft

patents

where one patent can have more than one assignee

Years Active: 2016-2025

Loading Chart...

16 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12195448 - Substituted pyrazolo piperidine carboxylic acids (2025-01-14),

2. 12138256 - Treatment of cardiopulmonary disorders (2024-11-12),

3. 12059472 - Prodrugs of cytotoxic active agents having enzymatically cleavable groups (2024-08-13),

4. 11685714 - Prodrugs of cytotoxic active agents having enzymatically cleavable groups (2023-06-27),

5. 11660351 - Antibody drug conjugates (ADCs) having enzymatically cleavable groups (2023-05-30),

6. 11478554 - Antibody drug conjugates (ADCS) having enzymatically cleavable groups (2022-10-25),

7. 11433140 - Specific antibody drug conjugates (ADCs) having KSP inhibitors (2022-09-06),

8. 11149018 - Substituted N-arylethyl-2-aminoquinoline-4-carboxamides and use thereof (2021-10-19),

9. 11136296 - Substituted-arylethyl-2-arylquinoline-4-carboxamides and use thereof (2021-10-05),

10. 11071788 - Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies (2021-07-27),

11. 10292970 - Heteroaryl-substituted imidazo[1,2-A]pyridines and their use (2019-05-21),

12. 10214526 - Substituted pyrazolo[1,5-a]-pyridine-3-carboxamides and use thereof (2019-02-26),

13. 10174021 - Substituted pyrazolo[1,5-A]pyridines and their use (2019-01-08),

14. 10150773 - N-substituted 8-[(2,6-difluorobenzyl)oxy]-2,6- dimethylimidazo[1,2-a]pyrazin-3-carboxamide derivatives as stimulators of soluble guanylate cyclase (SGC) for the treatment of cardiovascular diseases (2018-12-11),

15. 9771360 - Cyano-substituted imidazo[1,2-A]pyridinecarboxamides and their use (2017-09-26),

As you requested an article about inventor Lisa Dietz, who is a dedicated innovator pushing the boundaries of technology for a sustainable future, here is the content:

Title: Lisa Dietz - Pioneering Sustainable Solutions through Innovation

Introduction:

In the realm of innovative thinkers, Lisa Dietz stands out as a visionary inventor in the modern era, dedicated to creating a more sustainable future through her groundbreaking inventions.

Latest Patents:

With an impressive portfolio of 14 patents, Lisa's latest patents include "Prodrugs of cytotoxic active agents having enzymatically cleavable groups." This invention focuses on novel prodrugs that are designed to be cleaved by tumour-associated proteases, releasing cytotoxic drugs for the treatment and prevention of diseases, especially cancers.

Career Highlights:

Lisa Dietz has honed her expertise while working at prestigious companies such as Bayer Pharma Aktiengesellschaft and Bayer Aktiengesellschaft. Her innovative spirit and drive for excellence have led to significant advancements in the field of pharmaceuticals.

Collaborations:

Throughout her career, Lisa has collaborated with talented individuals such as Alexandros Vakalopoulos and Frank Wunder. Together, they have synergized their skills and knowledge to bring innovative solutions to life.

Conclusion:

In conclusion, Lisa Dietz's unwavering dedication to pushing the boundaries of technology and creating sustainable solutions cements her status as a pioneering inventor in the modern era. Her commitment to innovation and passion for making a positive impact on the world through her inventions truly sets her apart.

This text is generated by artificial intelligence and may not be accurate.